GQ1035 / GeneQuantum Healthcare - LARVOL DELTA

GQ1035: First-in-class ADC against novel targets for gastric cancer and ovarian cancer discovered via high-throughput screening (AACR 2026) - "In this screen, TopoIi-ADC and Exatecan-ADC demonstrated superior anti-tumor activity compared to other payload-based ADCs (e.g., DXd, MMAE, Eribulin). GQ1035 shows a promising efficacy profile against gastric and ovarian cancers in preclinical PDO and PDX models. This positions GQ1035 as a potential breakthrough therapy in an area of high unmet medical need. It stands as a pioneering example of the strategic shift in biomedicine from "by design" to "by screening"."

ADC • Gastric Cancer • Oncology • Ovarian Cancer • Solid Tumor • CLDN18 • FOLR1